narcolepsy
-
Sleep Health
Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy
Alkermes plc, a global biopharmaceutical company focused on developing innovative medicines in the fields of neuroscience and oncology, recently unveiled…
Read More » -
Sleep Health
FDA Grants Fast Track Designation to Lu AH69593 for the Treatment of Narcolepsy
The United States Food and Drug Administration (FDA) has officially granted Fast Track designation to Lu AH69593, an investigational oral…
Read More » -
Sleep Health
FDA Grants Fast Track Designation to Lundbeck’s Lu AH69593 for the Treatment of Narcolepsy
The pharmaceutical industry and the sleep medicine community are closely monitoring a significant regulatory development as H. Lundbeck A/S (Lundbeck)…
Read More » -
Sleep Health
Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting
Jazz Pharmaceuticals plc has announced its comprehensive presence at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, scheduled…
Read More » -
Sleep Health
The Cognitive Toll of Narcolepsy Type 1
For decades, the clinical understanding of Narcolepsy Type 1 (NT1) has been anchored by a specific pentad of symptoms: excessive…
Read More »
